Progyny (PGNY) vs Sotera Health (SHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Progyny (PGNY) has outperformed Sotera Health (SHC) over the past year, gaining 37.8% versus a gain of 11.3%. Over five years, SHC leads with a -31.5% price change compared with -50.8% for PGNY. Sotera Health is the larger company by market cap ($5.09 billion vs $2.14 billion), about 2.4 times the size.
On valuation, Progyny trades at a lower forward P/E (12.0x vs 16.6x for Sotera Health).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PGNY | SHC |
|---|---|---|
| Share price | $27.83 | $17.83 |
| Market cap | $2.14B | $5.09B |
| 1-day change | +1.02% | -0.39% |
| YTD return | +7.28% | +1.47% |
| 1-year return | +37.75% | +11.32% |
| 5-year return | -50.79% | -31.55% |
| P/E ratio (TTM) | 30.25 | 31.28 |
| Forward P/E | 12.00 | 16.59 |
| EPS (TTM) | $0.92 | $0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.16B |
| Revenue growth (YoY) | — | +5.74% |
| Net income (latest FY) | — | $77.95M |
| Gross margin | — | 55.48% |
| Net margin | — | 6.70% |
| 52-week high | $33.07 | $19.85 |
| 52-week low | $16.10 | $13.09 |
| Distance from 52-week high | -15.83% | -10.18% |
| Analyst consensus | none | buy |
| Avg. price target upside | +23.68% | +27.43% |
| Average volume | 1.14M | 2.51M |
| Shares outstanding | 76.73M | 285.37M |
| Employees | 835 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sotera Health is about 2.4 times larger than Progyny by market value ($5.09B vs $2.14B).
- PGNY has outperformed SHC by 26.4 percentage points over the past year.
About Progyny
PGNY stock →Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.
Health Care · Misc Health and Biotechnology Services · 835 employees
About Sotera Health
SHC stock →Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs.
Health Care · Misc Health and Biotechnology Services · 3,000 employees
PGNY vs SHC FAQ
Which is bigger, Progyny or Sotera Health?
Sotera Health (SHC) is larger, with a market capitalization of $5.09B compared with $2.14B for Progyny (PGNY).
Which stock has performed better over the past year, PGNY or SHC?
PGNY returned +37.75% over the past 12 months, compared with +11.32% for SHC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PGNY or SHC?
PGNY has the lower trailing P/E at 30.3, versus 31.3 for SHC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Progyny and Sotera Health in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.